1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. California >
  6. Blacksmith Medicines Acquires Forge Therapeutics

M&A Deal Summary

Blacksmith Medicines Acquires Forge Therapeutics

On January 1, 2023, Blacksmith Medicines acquired life science company Forge Therapeutics

Acquisition Highlights
  • This is Blacksmith Medicines’ 1st transaction in the Life Science sector.
  • This is Blacksmith Medicines’ 1st transaction in the United States.
  • This is Blacksmith Medicines’ 1st transaction in California.

M&A Deal Summary
Date 2023-01-01
Target Forge Therapeutics
Sector Life Science
Buyer(s) Blacksmith Medicines
Deal Type Merger

Target

Forge Therapeutics

San Diego, California, United States
Forge Therapeutics is a developer of novel antibiotics targeting bacterial metalloenzymes. Forge aims to develop entirely novel classes of anti-infectives able to effectively treat patients infected with antimicrobial resistant pathogens. Forge Therapeutics is based in San Diego, California.

Search 214,981 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Blacksmith Medicines

San Diego, California, United States
Category Company
Sector Life Science
DESCRIPTION

Blacksmith Medicines is developing medicines targeting metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes, oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes. Blacksmith Medicines is based in San Diego, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal